News
CASI
0.7850
+1.58%
0.0122
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 7h ago
Weekly Report: what happened at CASI last week (1222-1226)?
Weekly Report · 1d ago
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026
TipRanks · 6d ago
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules
Seeking Alpha · 6d ago
CASI Pharmaceuticals Granted Extension Through February 17, 2026 To Regain Nasdaq Compliance
Benzinga · 6d ago
CASI Pharmaceuticals Faces Nasdaq Delisting Risk Pending Compliance with Listing Standards
Reuters · 6d ago
Weekly Report: what happened at CASI last week (1215-1219)?
Weekly Report · 12/22 10:30
Weekly Report: what happened at CASI last week (1208-1212)?
Weekly Report · 12/15 10:39
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study
TipRanks · 12/11 14:49
CASI Pharmaceuticals Secures $20M Convertible Note Investment To Fund Phase 1 Renal Transplant Study In China
Benzinga · 12/11 14:12
Casi Pharmaceuticals enters into $20M convertible note financing
TipRanks · 12/11 14:05
Buy Rating for CASI Pharmaceuticals: Promising CID-103 Clinical Data and Competitive Positioning
TipRanks · 12/09 11:26
Casi Pharmaceuticals announces CID-103 immune thrombocytopenia study results
TipRanks · 12/08 14:15
CASI Pharmaceuticals Highlights Results From CID-103 Immune Thrombocytopenia Study Study At Annual ASH Meeting
Benzinga · 12/08 14:04
CASI Pharmaceuticals Reports Positive Phase 1 Results for CID-103 in Immune Thrombocytopenia
Reuters · 12/08 14:00
Weekly Report: what happened at CASI last week (1201-1205)?
Weekly Report · 12/08 10:37
Weekly Report: what happened at CASI last week (1124-1128)?
Weekly Report · 12/01 10:32
Weekly Report: what happened at CASI last week (1117-1121)?
Weekly Report · 11/24 10:37
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman
Reuters · 11/19 14:00
Weekly Report: what happened at CASI last week (1110-1114)?
Weekly Report · 11/17 10:38
More
Webull provides a variety of real-time CASI stock news. You can receive the latest news about Casi Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CASI
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.